Summary
In a double-blind study with parallel groups a new controlled-release (CR) formulation of metoprolol1, 100 mg once daily, was compared with conventional metoprolol tablets, 100 mg once daily, in 27 patients with primary hypertension.
Exercise tests on a bicycle ergometer were undertaken 24 h after intake of the last dose of the drug following a four-week placebo run-in period and after four weeks of active treatment.
Heart rate, measured in the supine position and during exercise at the highest comparable workload, was reduced significantly more by metoprolol CR (p<0.05), thus indicating a higher degree of β1-blockade at the end of the dose interval with metoprolol CR. There was a greater reduction in supine systolic pressure (p<0.05) but not in supine diastolic pressure after metoprolol CR than after conventional tablets at 24 h. There was no significant difference between the two groups with respect to reduction in systolic blood pressure during exercise.
The 24-h plasma concentrations of metoprolol CR and conventional tablets correlated with the effects on heart rate, but not with blood pressure.
The tolerability of metoprolol CR was comparable with that of metoprolol administered as conventional tablets.
In conclusion, there was significantly greater β1-blockade 24 h after the intake of drug after metoprolol CR compared with conventional tablets.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yusuf S, Peto R, Lewis J, Colins R, Sleight P (1985) Beta-blockade during and after myocardial infarction. An overview of the randomized trials. Prog Cardiovasc Dis 27: 335–371
Olsson G, Rehnqvist N, Sjögren A, Erhardt L, Lundman T (1985) Long-term treatment with metoprolol after myocardial infarction: Effect on 3 year mortality and morbidity. JACC 5: 1428–1437
Wilcox RG, Hampton JR (1981) Comparative study of atenolol, metoprolol, metoprolol Durules, and slow-release oxprenolol in essential hypertension. Br Heart J 46: 498–502
Ragnarsson G, Sandberg A, Jonsson UE, Sjögren J (1987) Development of a new controlled release metoprolol product. Drug Dev Ind Pharm 13: 1495–1509
Sandberg A, Blomqvist I, Jonsson UE, Lundborg P (1988) Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets. Eur J Clin Pharmacol 33 [Suppl]: S9–S13
Åström H, Jonsson B (1976) Design of exercise test with special reference to heart patients. Br Heart J 38: 289–296
Åström H (1986) Exercise testing in patients with heart disease. Acta Pharmacol Toxicol (Copenh) 86 [Suppl 6]: 65–70
Borg G (1970) Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 2: 92–98
Johnsson G, Jordö L, Lundborg P, Regårdh C-G, Rönn O (1980) Plasma levels and pharmacological effects of metoprolol administered as controlled release (Durules) and ordinary tablets in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 18: 292–297
Johnsson G, Regårdh C-G, Sölvell L (1975) Combined pharmacokinetic and pharmacodynamic studies in man of the adrenergic β1-receptor antagonist metoprolol. Acta Pharmacol Toxicol (Copenh) 36 [Suppl 5]: 31–44
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rydén, L., Kristensson, B.E. & Westergren, G. Effect of controlled-release metoprolol on blood pressure and exercise heart rate in hypertension: A comparison with conventional tablets. Eur J Clin Pharmacol 33 (Suppl 1), S33–S37 (1988). https://doi.org/10.1007/BF00578410
Issue Date:
DOI: https://doi.org/10.1007/BF00578410